NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 212)
Posted On: 10/24/2023 5:40:00 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation for further studies, the company noted. NNA segments are designed to bring a company additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.
The audio news release covers Longeveron’s recent news regarding positive top-line results from its phase 2a trial of its investigational product Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation for further studies, the company noted. NNA segments are designed to bring a company additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.
The audio news release covers Longeveron’s recent news regarding positive top-line results from its phase 2a trial of its investigational product Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the news release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)